Appendix 3Y x 5
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity Actinogen Medical Limited
ABN 14 086 778 476
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Dr Geoffrey Brooke
Date of last notice 26 March 2026
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest 1. Direct
2. Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
2. HSBC Custody Nominees (Australia) Limited <A/C 2> -
beneficiary
Date of change 24 June 2026
No. of securities held prior
to change
1. 22,500,000 fully paid ordinary shares issued pursuant to
Employee Share Plan.
1,554,039 fully paid ordinary shares
275,331 unlisted options ex @ $0.0375 exp 11/9/2026
501,689 unlisted options ex @ $0.05 exp 31/5/2027
2. 5,825,890 fully paid ordinary shares.
237,029 unlisted options ex @ $0.0375 exp 11/9/2026
87,543 unlisted options ex @ $0.05 exp 31/5/2027
1,250,001 listed options ex @ $0.05 exp 30/9/2027
Class Fully paid ordinary shares
Number acquired 1. 9,000,000 fully paid ordinary shares
Number disposed -
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
Value/Consideration
includes brokerage/gst
Note: If consideration is non-cash, provide
details and estimated valuation
Deemed issue price of $0.0455 per share issued pursuant to
Employee Share Plan.
No. of securities held after
change
1. 31,500,000 fully paid ordinary shares issued pursuant to
Employee Share Plan.
1,554,039 fully paid ordinary shares
275,331 unlisted options ex @ $0.0375 exp 11/9/2026
501,689 unlisted options ex @ $0.05 exp 31/5/2027
3. 5,825,890 fully paid ordinary shares.
237,029 unlisted options ex @ $0.0375 exp 11/9/2026
87,543 unlisted options ex @ $0.05 exp 31/5/2027
1,250,001 listed options ex @ $0.05 exp 30/9/2027
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
Issue of shares pursuant to the Employee Share Plan as approved
by shareholders at the General Meeting held on 23 June 2026.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
N/A
Interest after change N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
N/A
If so, was prior written clearance provided to allow the trade
to proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity Actinogen Medical Limited
ABN 14 086 778 476
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Dr Steven Gourlay
Date of last notice 13 May 2026
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest 1. Direct
2. Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
2. SG Gourlay Nominees Pty Ltd <SG Gourlay Family A/C> -
Director of trustee and beneficiary of trust
Date of change 24 June 2026
No. of securities held prior to
change
1. 89,362,300 fully paid ordinary shares issued pursuant to
Employee Share Plan.
53,611,567 fully paid ordinary shares.
1,757,440 listed options ex @ $0.05 exp 31/5/2027
25,000,000 listed options ex $0.05 exp 30/9/2027
2. 22,301,690 fully paid ordinary shares.
642,560 listed options ex @ $0.05 exp 31/5/2027
Class Fully paid ordinary shares
Number acquired 1. 38,000,000 fully paid ordinary shares
Number disposed -
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
Value/Consideration
includes brokerage/gst
Note: If consideration is non-cash, provide
details and estimated valuation
Deemed issue price of $0.0455 per share issued pursuant to
Employee Share Plan.
No. of securities held after
change
1. 127,362,300 fully paid ordinary shares issued pursuant to
Employee Share Plan.
53,611,567 fully paid ordinary shares.
1,757,440 listed options ex @ $0.05 exp 31/5/2027
25,000,000 listed options ex $0.05 exp 30/9/2027
2. 22,301,690 fully paid ordinary shares.
642,560 listed options ex @ $0.05 exp 31/5/2027
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
Issue of shares pursuant to the Employee Share Plan as approved
by shareholders at the General Meeting held on 23 June 2026.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
N/A
Interest after change N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above
traded during a +closed period where prior written clearance
was required?
N/A
If so, was prior written clearance provided to allow the trade to
proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity Actinogen Medical Limited
ABN 14 086 778 476
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Mr Malcolm McComas
Date of last notice 26 March 2026
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest 1. Direct
2. Indirect
3. Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
2. Bunyula Super Pty Ltd <Bunyula Super Fund A/C> -
director related entity and contingent beneficial interest
3. McComas Capital Pty Ltd <McComas Family A/C> -
controller of trustee & a beneficiary of the trust
4. Speech Dynamics Pty Ltd – director related entity
Date of change 24 June 2026
No. of securities held prior
to change
1. 6,500,000 fully paid ordinary shares issued pursuant to
Employee Share Plan
300,000 fully paid ordinary shares
150,000 listed options ex @ $0.05 exp 31/5/2027
2. 1,070,219 fully paid ordinary shares
90,554 unlisted options ex @ $0.0375 exp 11/9/2026
33,445 unlisted options ex @ $0.05 exp 31/5/2027
3. 1,000,000 fully paid ordinary shares issued pursuant to
Employee Share Plan
301,617 fully paid ordinary shares
110,133 unlisted options ex @ $0.0375 exp 11/9/2026
40,676 listed options ex @ $0.05 exp 31/5/2027
4. 1,714,286 fully paid ordinary shares
750,000 listed options ex $0.05 exp 30/9/2027
Class Fully paid ordinary shares
Number acquired 1. 3,000,000 fully paid ordinary shares
Number disposed -
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
Value/Consideration
includes brokerage/gst
Note: If consideration is non-cash, provide
details and estimated valuation
Deemed issue price of $0.0455 per share issued pursuant to
Employee Share Plan.
No. of securities held after
change
1. 9,500,000 fully paid ordinary shares issued pursuant to
Employee Share Plan
300,000 fully paid ordinary shares
150,000 listed options ex @ $0.05 exp 31/5/2027
2. 1,070,219 fully paid ordinary shares
90,554 unlisted options ex @ $0.0375 exp 11/9/2026
33,445 unlisted options ex @ $0.05 exp 31/5/2027
3. 1,000,000 fully paid ordinary shares issued pursuant to
Employee Share Plan
301,617 fully paid ordinary shares
110,133 unlisted options ex @ $0.0375 exp 11/9/2026
40,676 listed options ex @ $0.05 exp 31/5/2027
4. 1,714,286 fully paid ordinary shares
750,000 listed options ex $0.05 exp 30/9/2027
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
Issue of shares pursuant to the Employee Share Plan as approved
by shareholders at the General Meeting held on 23 June 2026.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
N/A
Interest after change N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
N/A
If so, was prior written clearance provided to allow the trade
to proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
Appendix 3Y
Change of Director’s Interest Notice
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity Actinogen Medical Limited
ABN 14 086 778 476
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Dr George Morstyn
Date of last notice 26 March 2026
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest 1. Direct
2. Indirect
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
2. HSBC Custody Nominees (Australia) Limited <A/C 2> -
beneficiary
Date of change 24 June 2026
No. of securities held prior
to change
1. 4,665,280 fully paid ordinary shares
7,500,000 fully paid ordinary shares issued pursuant to
Employee Share Plan.
299,805 unlisted options ex @ $0.0375 exp 11/9/2026
260,728 listed options ex @ $0.05 exp 31/5/2027
2. 5,298,174 fully paid ordinary shares.
307,269 unlisted options ex @ $0.0375 exp 11/9/2026.
113,485 listed options ex @ $0.05 exp 31/5/2027
1,250,001 listed options ex @ $0.05 exp 30/9/2027
Class Fully paid ordinary shares
Number acquired 1. 3,000,000 fully paid ordinary shares
Number disposed -
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
Value/Consideration
includes brokerage/gst
Note: If consideration is non-cash, provide
details and estimated valuation
Deemed issue price of $0.0455 per share issued pursuant to
Employee Share Plan.
No. of securities held after
change
1. 4,665,280 fully paid ordinary shares
10,500,000 fully paid ordinary shares issued pursuant to
Employee Share Plan.
299,805 unlisted options ex @ $0.0375 exp 11/9/2026
260,728 listed options ex @ $0.05 exp 31/5/2027
2. 5,298,174 fully paid ordinary shares.
307,269 unlisted options ex @ $0.0375 exp 11/9/2026.
113,485 listed options ex @ $0.05 exp 31/5/2027
1,250,001 listed options ex @ $0.05 exp 30/9/2027
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
Issue of shares pursuant to the Employee Share Plan as approved
by shareholders at the General Meeting held on 23 June 2026.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in relation
to which the interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
N/A
Interest after change N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above
traded during a +closed period where prior written clearance
was required?
N/A
If so, was prior written clearance provided to allow the trade
to proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 1
Rule 3.19A.2
Appendix 3Y
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity Actinogen Medical Limited
ABN 14 086 778 476
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the
director for the purposes of section 205G of the Corporations Act.
Name of Director Dr Nicki Vasquez
Date of last notice 26 March 2026
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Direct or indirect interest Direct
Nature of indirect interest
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
N/A
Date of change 24 June 2026
No. of securities held prior
to change
7,500,000 fully paid ordinary shares issued pursuant to
Employee Share Plan
448,724 fully paid ordinary shares
183,334 listed options ex @ $0.05 exp 31/5/2027
Class Fully paid ordinary shares
Number acquired 3,000,000 fully paid ordinary shares
Number disposed -
Value/Consideration
includes brokerage/gst
Note: If consideration is non-cash, provide
details and estimated valuation
Deemed issue price of $0.0455 per share issued pursuant to
Employee Share Plan.
Appendix 3Y
Change of Director’s Interest Notice
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
No. of securities held after
change
10,500,000 fully paid ordinary shares issued pursuant to
Employee Share Plan
448,724 fully paid ordinary shares
183,334 listed options ex @ $0.05 exp 31/5/2027
Nature of change
Example: on-market trade, off-market trade,
exercise of options, issue of securities under
dividend reinvestment plan, participation in
buy-back
Issue of shares pursuant to the Employee Share Plan as approved
by shareholders at the General Meeting held on 23 June 2026.
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be
disclosed in this part.
Detail of contract N/A
Nature of interest N/A
Name of registered holder
(if issued securities)
N/A
Date of change N/A
No. and class of securities to
which interest related prior to
change
Note: Details are only required for a contract in relation
to which the interest has changed
N/A
Interest acquired N/A
Interest disposed N/A
Value/Consideration
Note: If consideration is non-cash, provide details and an
estimated valuation
N/A
Interest after change N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed
above traded during a +closed period where prior written
clearance was required?
N/A
If so, was prior written clearance provided to allow the trade
to proceed during this period?
N/A
If prior written clearance was provided, on what date was this
provided?
N/A
Share your feedback
Discover